• search

TGA certification for Ind-Swift Labs

Written by: Staff
|

Chandigarh, Mar 23 (UNI) Leading pharma Ind-Swift Laboratories Ltd has achieved an important milestone by obtaining the Therapeutic Goods Administration (TGA) certification from the Australian Common Wealth Department of Health and Ageing for its manufacturing facility for the 1.18 billion dollar drug 'clarithromycin'.

Describing it as'' a significant achievement'' Mr V K Mehta, joint managing Director of the company said here today the company is focusing on the regulated markets for its growth and the TGA certification will leverage the company's intrinsic potential and place it at par with the other leading players in the industry.

Ind-Swift Laboratories is one of the largest manufacturers of clarithromycin in the world and enjoys 30 to 33 per cent of the world market share for this drug.

The Australian Department has recommended that ''the company complies with the requirement of the Australian Code of Good Manufacturing Practice for medicinal products, for the range of products to be supplied to Australia''.

The company has launched four new Active Pharmaceuitical ingrdients (APIS) which include Letrozole (Aromtase Inhibitor), Quetiapine Fumerate (Anti-Psychotic), Aripiprazole (Anti-Pshycotic) and Ropinirole (Parkinsons Disease).

Mr Mehta said the company had recently inked a joint venture with an Iranian Company. The joint venture will primarily focus on manufacturing of APIs in Iran and its marketing in the Middle East and partS of Europe.

Besides the main manufacuring facilities situated at Derabassi in Punjab, the company's other facility Jammu is primarily focused on manufacturing of API for the domestic market.

UNI HS BP SD VC1540

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more